Kymera Therapeutics Inc KYMR

$110.76 -0.09 (-0.08%)

Valuation

Market cap
9,217,288,000
Revenue TTM
$39,210,000
Net income TTM
$-311,350,000
PE ratio
0.00
Forward PE
—
Profit margin
-794.06%
Debt to equity
0.00

Trading

Volume
517,000
Avg volume
756,808
Day's range
$109.05 – $111.82
Shares out
83,151,000
Stochastic %K
56%
Beta
1.98
Analysts
Strong Sell
Price target
$138.39

Price

Company profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, an...

Show more

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 285 5300
Website
https://www.kymeratx.com
Address
500 North Beacon Street, 4th Floor, Watertown, United States

Latest news

Stocktwits

Seabass1459 Oct 23, 3:17 PM
$KYMR my spidey senses are tingling hmmm
0 replies
Merlintrader Oct 16, 8:09 AM
Kymera's oral STAT6 degrader KT-621: the Phase 2b BROADEN2 trial in atopic dermatitis has topline data expected by year-end 2026, with Phase 3 planned by mid-2027; cash and investments were $1.5 billion at June 30, 2026 (company, August 5, 2026). Latest company news, September 1, 2026: timing reaffirmed. More details in our $KYMR hub on our site. Not investment advice.
0 replies
chartistmind Oct 8, 7:52 PM
$CELC $IMVT $KYMR $PBLS $ROIV stop making an example out of me! Jerks
0 replies
chartistmind Oct 8, 5:22 PM
$CELC $PBLS $IMVT $ROIV $KYMR all the good 📈 setups are in biotech but they could drop data that slashes you in half so no thanks.
0 replies
Quantumup Oct 5, 12:37 PM
Citi⬆️ $KYMR's PT to $150,⬆️2032 KT-621 penetration ests to 6% and risk-adj'd peak sales to $2.5B while Adding to its Upside 90-day Catalyst Watch; maintained Buy ahead of Phase 2b BROADEN2 readout in AD (YE26e). $REGN - $SNY APGE - ABBV CRVS NKTR GSk AUPH NVS RHHBY Here's what Citi said in its note: https://x.com/Quantumup1/status/2107087507942764659?s=20
0 replies
Merlintrader Sep 27, 7:54 AM
Can removing a protein change treatment? $CCCC, $KYMR, $NRIX, $RIGL C4 Therapeutics, Kymera, Nurix and Rigel reveal different paths from eliminating a protein to improving a patient’s outcome. Mechanism, tissue, evidence and retained rights determine the opportunity. https://www.merlintrader.com/protein-degradation-protacs-cccc-kymr-nrix-rigl/
0 replies
MaverikIT Sep 22, 6:19 PM
$VKTX $TGTX $MANE $KYMR LFG
0 replies
anachartanalyst Sep 22, 11:01 AM
$KYMR https://anachart.com/wp-content/uploads/2026/09/1790074889_soc-img.jpg
0 replies